PALYNZIQ Trademark

Trademark Overview

On Wednesday, July 5, 2017, a trademark application was filed for PALYNZIQ with the United States Patent and Trademark Office. The USPTO has given the PALYNZIQ trademark a serial number of 87978318. The federal status of this trademark filing is REGISTERED as of Tuesday, October 2, 2018. This trademark is owned by Biomarin Pharmaceutical Inc.. The PALYNZIQ trademark is filed in the Medical & Beauty Services & Agricultural Services category with the following description:

Provide medical information related to the treatment of genetic diseases and disorders, the use of enzyme therapy
palynziq

General Information

Serial Number87978318
Word MarkPALYNZIQ
Filing DateWednesday, July 5, 2017
Status700 - REGISTERED
Status DateTuesday, October 2, 2018
Registration Number5577454
Registration DateTuesday, October 2, 2018
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, November 7, 2017

Trademark Statements

Description of MarkThe mark consists of an upper-case letter of "P" and the lower-case letters of "alyniq" in navy blue color; the lower-case letter of "z" which has a top and a bottom horizontal lines in navy blue color, with a middle line in light green color.
Indication of Colors claimedThe color(s) navy blue and light green is/are claimed as a feature of the mark.
Goods and ServicesProvide medical information related to the treatment of genetic diseases and disorders, the use of enzyme therapy

Classification Information

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, July 12, 2017
Primary Code044
First Use Anywhere DateSaturday, May 26, 2018
First Use In Commerce DateSaturday, May 26, 2018

Trademark Owner History

Party NameBiomarin Pharmaceutical Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressNovato, CA 94949
Party NameBiomarin Pharmaceutical Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNovato, CA 94949
Party NameBiomarin Pharmaceutical Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNovato, CA 94949

Trademark Events

Event DateEvent Description
Wednesday, July 12, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, July 8, 2017NEW APPLICATION ENTERED
Thursday, September 28, 2017ASSIGNED TO EXAMINER
Thursday, September 28, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 18, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 7, 2017PUBLISHED FOR OPPOSITION
Tuesday, November 7, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 2, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, June 28, 2018TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, June 28, 2018SOU TEAS EXTENSION RECEIVED
Thursday, June 28, 2018SOU EXTENSION 1 FILED
Thursday, June 28, 2018SOU EXTENSION 1 GRANTED
Saturday, June 30, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 26, 2018TEAS STATEMENT OF USE RECEIVED
Thursday, July 26, 2018TEAS REQUEST TO DIVIDE RECEIVED
Thursday, July 26, 2018DIVISIONAL REQUEST RECEIVED
Tuesday, August 14, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, August 29, 2018NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Thursday, July 26, 2018USE AMENDMENT FILED
Monday, August 27, 2018DIVISIONAL PROCESSING COMPLETE
Monday, August 27, 2018STATEMENT OF USE PROCESSING COMPLETE
Tuesday, August 28, 2018ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, December 9, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, December 9, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, December 9, 2020TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, December 9, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, July 30, 2024TEAS SECTION 8 & 15 RECEIVED
Monday, October 2, 2023COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, October 2, 2018REGISTERED-PRINCIPAL REGISTER

Related Keywords

palynziq diseases disorders enzyme therapy genetic treatment medical information related provide